Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | CTSE | P14091 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7012505 | 0.88 | TACR1 (0.43) | TACR1KDM4EMAPTTHRBDDB1 | |
| SCHEMBL3492232 | 0.87 | TACR1 (0.43) | TACR1KDM4EMAPTTHRBDDB1 | |
| SCHEMBL21753397 | 0.87 | NPC1 (0.43) | TACR1KDM4EMAPTTHRBDDB1 | |
| SCHEMBL4136918 | 0.84 | KDM4E (0.44) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL2916974 | 0.83 | TSHR (0.40) | TACR1KDM4EMAPTTHRBDDB1 | |
| SCHEMBL23288913 | 0.83 | OPRD1 (0.46) | TACR1MAPTCCR5OPRD1OPRK1 | |
| SCHEMBL21150761 | 0.82 | MEN1 (0.40) | TACR1GPR119 | |
| SCHEMBL5820043 | 0.80 | LMNA (0.47) | MAPTTHRBBACE1TP53SMN1; SMN2 | |
| SCHEMBL8811737 | 0.80 | TSHR (0.38) | TACR1KDM4EMAPTTHRBDDB1 | |
| SCHEMBL8809557 | 0.80 | KDM4E (0.42) | TACR1KDM4EMAPTTHRBDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | TACR1 76/4885KDM4E 2126/4885MAPT 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.